Leerink Partnrs Has Strong Outlook for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Compass Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.39) per share for the year, up from their previous estimate of ($0.40). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.35) per share. Leerink Partnrs also issued estimates for Compass Therapeutics' Q4 2024 earnings at ($0.14) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.99) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Other research analysts also recently issued reports about the company. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners downgraded Compass Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, Jefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.17.

Compass Therapeutics Trading Down 8.0 %

Compass Therapeutics stock traded down $0.30 during midday trading on Monday, hitting $3.45. The stock had a trading volume of 1,260,215 shares, compared to its average volume of 2,317,134. The company has a market capitalization of $474.68 million, a PE ratio of -9.32 and a beta of 1.17. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The firm's fifty day moving average is $2.24 and its two-hundred day moving average is $1.78.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. SG Americas Securities LLC grew its stake in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after purchasing an additional 356,352 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Compass Therapeutics by 512.5% in the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after acquiring an additional 227,864 shares in the last quarter. Barclays PLC boosted its holdings in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company's stock worth $314,000 after acquiring an additional 112,614 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock worth $141,000 after acquiring an additional 70,200 shares in the last quarter. Finally, Catalina Capital Group LLC acquired a new stake in Compass Therapeutics in the fourth quarter worth about $71,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.